ABSTRACT
AMP-activated protein kinase (AMPK) is activated by upstream kinases and negatively regulated by protein phosphatases. Intracellular calcium mediates protein phosphatase 2A (PP2A), which is in a heterotrimeric complex with the PR72 subunit. The PR72 subunit contains two calcium-binding sites formed by EF hands. Our previous study has shown that chronic calcium exposure decreases AMPK activity. To define the specific molecular mechanism whereby calcium can deactivate AMPK, activities of AMPK and PP2A were analyzed in C2C12 muscle cell cultures and skeletal muscle tissues from mutant pigs possessing the AMPKγ3-mutation or the ryanodine receptor (RyR1) calcium gating mutation, or both. C2C12 myotubes treated with calcium releasing agent (caffeine) for 10h decreased (P<0.05) AICAR-induced AMPK activity to control levels and this negative effect was eliminated by ryanodine receptor stabilizer, dantrolene. Interestingly, muscle from pigs with the RyR1 mutation and C2C12 cells administered with 10h caffeine showed higher (P<0.05) PP2A activity compared to controls. More importantly, the inhibitory effect of caffeine on AMPK activity was attenuated by the PP2A inhibitor, calyculin A or siRNA induced knockdown of PP2A. These data show the inhibitory effect of chronic calcium on AMPK activity is exerted through the activation of PP2A.
Subject(s)
AMP-Activated Protein Kinases/metabolism , Calcium/metabolism , Protein Phosphatase 2/metabolism , AMP-Activated Protein Kinases/antagonists & inhibitors , Animals , Caffeine/pharmacology , Cells, Cultured , Dose-Response Relationship, Drug , Marine Toxins , Oxazoles/pharmacology , Protein Kinase Inhibitors/pharmacology , Protein Phosphatase 2/antagonists & inhibitors , RNA, Small Interfering/pharmacology , Structure-Activity Relationship , SwineABSTRACT
Chronic atrial fibrillation (AF) is characterized by decreased atrial contractility, shortened action potential duration, and decreased accommodation of action potential duration to changes in activation rate. Studies on experimental animal models of AF implicate a reduction in L-type Ca2+ current (I(Ca)) density in these changes. To evaluate the effect of AF on human I(Ca), we compared I(Ca) in atrial myocytes isolated from 42 patients in normal sinus rhythm at the time of cardiac surgery with that of 11 chronic AF patients. I(Ca) was significantly reduced in the myocytes of patients with chronic AF (mean -3.35+/-0.5 pA/pF versus -9.13+/-1. 0 pA/pF in the controls), with no difference between groups in the voltage dependence of activation or steady-state inactivation. Although I(Ca) was lower in myocytes from the chronic AF patients, their response to maximal beta-adrenergic stimulation was not impaired. Postoperative AF frequently follows cardiac surgery. Half of the patients in the control group (19/38) of this study experienced postoperative AF. Whereas chronic AF is characterized by reduced atrial I(Ca), the patients with the greatest I(Ca) had an increased incidence of postoperative AF, independent of patient age or diagnosis. This observation is consistent with the concept that calcium overload may be an important factor in the initiation of AF. The reduction in functional I(Ca) density in myocytes from the atria of chronic AF patients may thus be an adaptive response to the arrhythmia-induced calcium overload.
Subject(s)
Atrial Fibrillation/physiopathology , Calcium Channels/physiology , Calcium Signaling , Action Potentials/drug effects , Adrenergic beta-Agonists/pharmacology , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/drug therapy , Atrial Fibrillation/etiology , Atrial Fibrillation/surgery , Calcium/metabolism , Calcium Channel Blockers/pharmacology , Calcium Channels/biosynthesis , Calcium Channels/drug effects , Calcium Channels/genetics , Calcium Channels, L-Type , Calcium Signaling/drug effects , Cells, Cultured , Chronic Disease , Coronary Artery Bypass , Disease Susceptibility , Female , Gene Expression Regulation , Heart Atria/pathology , Heart Atria/physiopathology , Heart Conduction System/physiopathology , Heart Transplantation , Heart Valve Prosthesis Implantation , Humans , Ion Channel Gating/drug effects , Ion Transport/drug effects , Isoproterenol/pharmacology , Male , Middle Aged , Muscle Proteins/biosynthesis , Muscle Proteins/genetics , Myocardial Contraction/drug effects , Nifedipine/pharmacology , Patch-Clamp Techniques , Postoperative Complications/physiopathologyABSTRACT
Neurotensin (NT), a neuropeptide found both centrally and peripherally, stimulated release of histamine from rat peritoneal mast cells in a dose-dependent manner. Release was evident by 10 nM and reached a plateau of 15-20% total cellular histamine by 10(-7)-10(-6) M NT. Optimal conditions for stimulation occurred at pH 6.5-7.5, 37 degrees C and at calcium concentrations of less than 1 mM. Release was complete within 2 minutes of peptide addition. Studies of histamine release by NT analogues indicted that the C-terminus is the biologically active portion of the molecule in this system, as is true of all other systems responsive to NT (1). D-Trp11-NT, which acts as a NT antagonist in several peripheral NT-sensitive tissues (2,3), also inhibited NT action on mast cells. Manipulations involving Ca2+ availability suggest that the mechanism of NT stimulation may involve use of intracellular Ca2+ to a greater extent than extracellular Ca2+. Lowering the extracellular Ca2+ concentration or blocking influx of extracellular Ca2+ with lanthanum (La3+), had little effect on NT-induced release, whereas Ca2+ depletion by treatment with ethylenediaminetetracetic acid (EDTA) or blockade of intracellular Ca2+ mobilization by N,N-(diethylamino)octyl 3,4,5-trimethoxybenzoate (TMB-8), inhibited the response to NT. Increasing cellular levels of adenosine 3',5'-cyclic monophosphate (cAMP), by treatment with 8-bromo-cAMP or stimulation with prostaglandin E2 (PGE2) in the presence of isobutylmethylxanthine (IBMX), served to reduce histamine release by NT, indicating that cAMP may play a role in NT stimulation.
